MNKD MannKind Corporation Stock Quote

MNKD [NASD]

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	1.70%	Shs Outstand	249.29M	Perf Week	-20.61%
Market Cap	1.08B	Forward P/E	-	EPS next Y	-0.17	Insider Trans	0.25%	Shs Float	235.54M	Perf Month	-8.17%
Income	-86.10M	PEG	-	EPS next Q	-0.05	Inst Own	45.10%	Short Float	11.33%	Perf Quarter	-10.73%
Sales	74.50M	P/S	14.52	EPS this Y	3.10%	Inst Trans	0.53%	Short Ratio	9.39	Perf Half Y	-1.65%
Book/sh	-0.74	P/B	-	EPS next Y	43.30%	ROA	-44.40%	Target Price	6.17	Perf Year	108.00%
Cash/sh	0.63	P/C	6.65	EPS next 5Y	35.60%	ROE	47.60%	52W Range	1.91 - 6.25	Perf YTD	32.91%
Dividend	-	P/FCF	-	EPS past 5Y	43.70%	ROI	82.50%	52W High	-33.44%	Beta	1.87
Dividend %	-	Quick Ratio	2.90	Sales past 5Y	-	Gross Margin	61.10%	52W Low	117.80%	ATR	0.30
Employees	241	Current Ratio	3.00	Sales Q/Q	54.30%	Oper. Margin	-96.30%	RSI (14)	36.28	Volatility	5.17% 5.12%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-197.30%	Profit Margin	-	Rel Volume	6.43	Prev Close	5.09
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 11 AMC	Payout	-	Avg Volume	2.84M	Price	4.16
Recom	1.70	SMA20	-14.07%	SMA50	-9.65%	SMA200	-4.38%	Volume	16,779,688	Change	-18.27%

May-14-21

Initiated

RBC Capital Mkts

Sector Perform

Dec-24-19

Initiated

Oppenheimer

Outperform

$2.50

Oct-25-19

Initiated

Cantor Fitzgerald

Overweight

May-14-19

Initiated

BTIG Research

Buy

Mar-04-19

Initiated

SVB Leerink

Outperform

Feb-22-19

Initiated

SVB Leerink

Outperform

Feb-28-18

Downgrade

Maxim Group

Hold → Sell

Nov-01-17

Downgrade

Maxim Group

Buy → Hold

Oct-10-17

Initiated

H.C. Wainwright

Buy

Oct-06-17

Reiterated

Maxim Group

Buy

$4 → $7

Aug-11-17

Initiated

Maxim Group

Buy

May-10-16

Reiterated

RBC Capital Mkts

Underperform

$0.15 → $0.20

May-10-16

Reiterated

Piper Jaffray

Underweight

$0.05 → $0.10

Jan-06-16

Reiterated

RBC Capital Mkts

Underperform

$1 → $0.15

Jan-06-16

Reiterated

Piper Jaffray

Underweight

$1.50 → $0.05

Nov-04-15

Downgrade

RBC Capital Mkts

Outperform → Underperform

$9 → $1

Sep-09-15

Downgrade

Piper Jaffray

Neutral → Underweight

Aug-03-15

Reiterated

RBC Capital Mkts

Outperform

$10 → $9

May-11-15

Reiterated

MLV & Co

Hold

$7 → $4

May-11-15

Downgrade

JP Morgan

Neutral → Underweight

Oct-18-21 02:38PM	United Therapeutics hits speed bump in its quest for new drug approval American City Business Journals -18.27%
02:37PM	Mid-Afternoon Market Update: Dow Falls 70 Points; Evolving Systems Shares Spike Higher Benzinga
12:37PM	Why Shares of MannKind Corporation Are Falling This Morning Motley Fool
11:42AM	MannKind's stock falls 18% after FDA says it will not approve application for hypertension drug MarketWatch
09:20AM	Why MannKind Shares Are Falling Today Benzinga
08:45AM	FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease Benzinga
06:36AM	UPDATE 1-U.S. FDA declines to approve United-Mannkind's lung disease therapy Reuters
06:02AM	United Therapeutics, Mannkind Fall After FDA Declines to Approve Lung Drug Investing.com
06:00AM	Progress Update on Tyvaso DPI New Drug Application GlobeNewswire
Oct-04-21 08:11AM	Do Options Traders Know Something About MannKind (MNKD) Stock We Don't? Zacks
07:05AM	MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population PR Newswire
07:05AM	MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza® in Pediatric Population GlobeNewswire
Sep-30-21 07:43AM	The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga
Sep-29-21 04:24PM	Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds GlobeNewswire
Sep-28-21 10:05AM	As MannKind Corporation (NASDAQ:MNKD) gains 7.1%, insiders who bought last year may be wishing they had bet higher Simply Wall St.
06:05AM	MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference GlobeNewswire
Sep-15-21 06:05AM	Mannkind Corporation Participating at Upcoming Conferences GlobeNewswire
Sep-07-21 09:54AM	United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients Benzinga
06:05AM	MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
06:00AM	United Therapeutics Presents Tyvaso DPI BREEZE Clinical Data At The European Respiratory Society International Congress 2021 PR Newswire
Aug-14-21 03:40AM	US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results Simply Wall St.
Aug-12-21 11:30AM	MannKind Corporation (MNKD) Q2 2021 Earnings Call Transcript Motley Fool
Aug-11-21 05:15PM	MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:00PM	MannKind Corporation Reports 2021 Second Quarter Financial Results GlobeNewswire
Aug-04-21 06:48AM	NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI (aviptadil) Inhaler for Respiratory Conditions PR Newswire
06:48AM	MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI (aviptadil) Based On The Technosphere® Platform PR Newswire
06:15AM	MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021 GlobeNewswire
Aug-03-21 09:00AM	MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021 GlobeNewswire
Jul-29-21 11:00AM	INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th PR Newswire
Jul-28-21 03:03PM	MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-09-21 04:52AM	How Much Of MannKind Corporation (NASDAQ:MNKD) Do Institutions Own? Simply Wall St.
Jun-29-21 09:34AM	Company News for Jun 29, 2021 Zacks
Jun-28-21 06:15AM	Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza® And Continuous Glucose Monitoring Devices Beginning July 18 PR Newswire +11.60%
04:15AM	MannKind Can Climb Higher Based on Its Charts TheStreet.com
Jun-25-21 11:35AM	MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29 PR Newswire
Jun-17-21 09:40AM	United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag Zacks
Jun-16-21 10:59AM	MannKind And United Therapeutics Achieve A Major Milestone In The Development Of Tyvaso DPI With New Drug Application Acceptance From The FDA PR Newswire +5.61%
07:26AM	MannKind - United Therapeutics' Formulated Treprostinil Under FDA Review For Pulmonary Hypertension Benzinga
06:15AM	MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI With New Drug Application Acceptance From the FDA GlobeNewswire
06:00AM	United Therapeutics Announces FDA Acceptance of Tyvaso DPI New Drug Application For Priority Review PR Newswire
05:04AM	MannKind Shares Rise as Partner's Drug Gets FDA Priority Review TheStreet.com
Jun-10-21 06:15AM	MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases GlobeNewswire
Jun-08-21 05:00PM	MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference GlobeNewswire
Jun-03-21 06:00AM	MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5 PR Newswire
May-25-21 04:35AM	MannKind Corporation's (NASDAQ:MNKD) Path To Profitability Simply Wall St.
May-20-21 09:00AM	INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-karts With Local Youth On Tuesday, May 25th PR Newswire
May-13-21 09:00AM	MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly PR Newswire
09:00AM	MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly GlobeNewswire
08:30AM	MannKind Corporation (MNKD) Q1 2021 Earnings Call Transcript Motley Fool
May-12-21 04:00PM	MannKind Corporation Reports 2021 First Quarter Financial Results GlobeNewswire -8.64%
May-11-21 09:00AM	MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference GlobeNewswire +8.11%
May-05-21 09:00AM	MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021 GlobeNewswire
Apr-28-21 12:33PM	Earnings Preview: MannKind (MNKD) Q1 Earnings Expected to Decline Zacks
Apr-26-21 09:00AM	MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche GlobeNewswire
Apr-19-21 06:00AM	Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI With New Drug Application Submitted to the FDA GlobeNewswire
Mar-16-21 09:00AM	MannKind Announces Closing of Initial Purchasers Option to Purchase Additional Convertible Senior Notes GlobeNewswire
Mar-15-21 08:00AM	MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors GlobeNewswire
Mar-10-21 05:00PM	MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference GlobeNewswire
Mar-02-21 05:00PM	MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference GlobeNewswire -5.74%
06:30AM	MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering GlobeNewswire
Mar-01-21 07:00AM	MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes GlobeNewswire -29.77%
04:47AM	Can You Imagine How Elated MannKind's (NASDAQ:MNKD) Shareholders Feel About Its 350% Share Price Gain? Simply Wall St.
Feb-26-21 10:05AM	What Does MannKind's Debt Look Like? Benzinga
01:01AM	MannKind Corporation (MNKD) Q4 2020 Earnings Call Transcript Motley Fool
Feb-25-21 08:00AM	MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results GlobeNewswire -6.19%
Feb-24-21 02:57PM	Why MannKind Corporation Stock Is Popping Today Motley Fool +13.26%
08:00AM	Vertice launches THYQUIDITY (levothyroxine sodium) Oral Solution PR Newswire
Feb-18-21 05:00PM	MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference GlobeNewswire
09:00AM	MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021 GlobeNewswire
Feb-04-21 08:33PM	MannKind Stock Is up 60% in One Month; Is There Room for More Upside? TipRanks
Jan-04-21 05:00PM	MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference GlobeNewswire
Dec-29-20 08:53AM	MannKind (MNKD) Looks Good: Stock Adds 5.6% in Session Zacks -8.86%
Dec-18-20 07:45AM	The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga
Dec-17-20 04:44PM	MannKind and Vertice to Co-Promote Thyquidity (levothyroxine sodium) Oral Solution GlobeNewswire
Dec-10-20 08:00AM	James S. Shannon Transitions to Chairman of the Board of Directors for MannKind GlobeNewswire
Dec-07-20 11:33PM	Is MNKD A Good Stock To Buy Now? Insider Monkey -7.12%
09:20AM	MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc. GlobeNewswire
Dec-01-20 08:00AM	MannKind and MidCap Amend Credit Facility GlobeNewswire
Nov-30-20 08:00AM	Sabrina Kay Appointed to MannKind Board of Directors GlobeNewswire
Nov-20-20 07:37AM	The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga +5.07%
Nov-19-20 05:00PM	MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics GlobeNewswire
Nov-10-20 10:15AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MannKind Corporation for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire
Nov-08-20 09:37AM	Bearish: Analysts Just Cut Their MannKind Corporation (NASDAQ:MNKD) Revenue and EPS estimates Simply Wall St.
Nov-06-20 08:44PM	MannKind Stock: Next Stop, $4? TipRanks
Nov-04-20 05:15PM	MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:00PM	MannKind Corporation Reports 2020 Third Quarter Financial Results GlobeNewswire
Oct-29-20 08:00AM	MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020 GlobeNewswire
Oct-28-20 12:32PM	Will MannKind (MNKD) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-23-20 10:38AM	MannKind Corporation (NASDAQ:MNKD): When Will It Breakeven? Simply Wall St.
Sep-08-20 08:00AM	MannKind Corporation Participating at Upcoming Conferences GlobeNewswire
Aug-31-20 09:00AM	Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety GlobeNewswire
Aug-24-20 02:28PM	Key Things To Understand About MannKind's (NASDAQ:MNKD) CEO Pay Cheque Simply Wall St.
Aug-20-20 08:39AM	MannKind (MNKD) in Focus: Stock Moves 8.7% Higher Zacks
Aug-07-20 05:00PM	MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020 GlobeNewswire
Aug-05-20 06:35PM	MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates Zacks +12.05%
04:00PM	MannKind Corporation Reports 2020 Second Quarter Financial Results GlobeNewswire
Jul-29-20 05:00PM	MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020 GlobeNewswire
12:33PM	MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-20-20 09:00AM	Alejandro Galindo Joins MannKind as Chief Commercial Officer GlobeNewswire
Jun-22-20 08:30AM	MannKind (MNKD) Looks Good: Stock Adds 5.5% in Session Zacks +14.51%

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF- inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thomson David	EVP Genl Counsel & Secretary	Aug 27	Sale	4.64	4,100	19,024	567,391	Aug 27 09:01 PM
Castagna Michael	Chief Executive Officer	Jul 30	Buy	2.99	5,000	14,950	1,538,652	Aug 02 08:00 PM
Galindo Alejandro	Chief Commercial Officer	Jul 30	Buy	2.99	5,000	14,950	547,602	Aug 02 08:00 PM
Tross Stuart A	Chief People & Workpl Officer	Jul 30	Buy	2.99	4,476	13,383	634,708	Aug 02 08:00 PM
Binder Steven B.	Chief Financial Officer	Jul 30	Buy	2.99	748	2,237	547,644	Aug 02 08:00 PM
Castagna Michael	Chief Executive Officer	Mar 05	Buy	3.38	3,000	10,140	3,000	Mar 08 05:00 PM
Binder Steven B.	Chief Financial Officer	Jan 31	Buy	1.33	1,557	2,071	398,822	Feb 02 06:18 PM
Castagna Michael	Chief Executive Officer	Jan 31	Buy	1.33	5,000	6,650	1,117,560	Feb 02 06:18 PM
Tross Stuart A	Chief People & Workpl Officer	Jan 31	Buy	1.33	5,000	6,650	481,991	Feb 02 06:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience